...
首页> 外文期刊>Cancer biotherapy and radiopharmaceuticals >In Vitro Mouse and Human Serum Stability of a Heterobivalent Dual-Target Probe That Has Strong Affinity to Gastrin-Releasing Peptide and Neuropeptide Y1 Receptors on Tumor Cells
【24h】

In Vitro Mouse and Human Serum Stability of a Heterobivalent Dual-Target Probe That Has Strong Affinity to Gastrin-Releasing Peptide and Neuropeptide Y1 Receptors on Tumor Cells

机译:体外小鼠和人血清稳定性的异常双靶探针,其对肿瘤细胞的胃泌素释放肽和神经肽Y1受体具有很强的亲和力

获取原文
获取原文并翻译 | 示例
           

摘要

Receptor-targeting radiolabeled molecular probes with high affinity and specificity are useful in studying and monitoring biological processes and responses. Dual-or multiple-targeting probes, using radiolabeled metal chelates conjugated to peptides, have potential advantages over single-targeting probes as they can recognize multiple targets leading to better sensitivity for imaging and radiotherapy when target heterogeneity is present. Two natural hormone peptide receptors, gastrin-releasing peptide (GRP) and Y1, are specifically interesting as their expression is upregulated in most breast and prostate cancers. One of our goals has been to develop a dual-target probe that can bind both GRP and Y1 receptors. Consequently, a heterobivalent dual-target probe, t-BBN/BVD15-DO3A (where a GRP targeting ligand J-G-Abz4-QWAVGHLM-NH2 and Y1 targeting ligand INP-K [epsilon-J-(alpha-DO3A-epsilon-DGa)-K] YRLRY-NH2 were coupled), that recognizes both GRP and Y1 receptors was synthesized, purified, and characterized in the past. Competitive displacement cell binding assay studies with the probe demonstrated strong affinity (IC50 values given in parentheses) for GRP receptors in T-47D cells (18 +/- 0.7 nM) and for Y1 receptors in MCF7 cells (80 +/- 11 nM). As a further evaluation of the heterobivalent dual-target probe t-BBN/BVD15-DO3A, the objective of this study was to determine its mouse and human serum stability at 37 degrees C. The in vitro metabolic degradation of the dual-target probe in mouse and human serum was studied by using a Gd-153-labeled t-BBN/BVD15-DO3A and a high-performance liquid chromatography/radioisotope detector analytical method. The half-life (t(1/2)) of degradation of the dual-target probe in mouse serum was calculated as 7 hours and only similar to 20% degradation was seen after 6 hours incubation in human serum. The slow in vitro metabolic degradation of the dual-target probe can be compared with the degradation t1/2 of the corresponding monomeric probes, BVD15-DO3A and AMBA: 15, and similar to 40 minutes for BVD15-DO3A and 3.1 and 38.8 hours for AMBA in mouse and human serum, respectively. A possible pathway for in vitro metabolic degradation of the t-BBN/BVD15-DO3A in mouse serum is proposed based on the chromatographic retention times of the intact probe and its degradants.
机译:具有高亲和力和特异性的受体靶向放射性标记的分子探针可用于研究和监测生物过程和反应。使用与肽缀合的放射性标记金属螯合物的双或多靶向探针具有与单靶标探针相比的潜在优点,因为它们可以识别多个靶标,导致在存在目标异质性时,导致对成像和放射疗法的更好敏感性。两种天然激素肽受体,胃泌素释放肽(GRP)和Y1特别有趣,因为它们的表达在大多数乳腺和前列腺癌中上调。我们的目标之一是开发可以结合GRP和Y1受体的双重靶探针。因此,异常双靶探针,T-BBN / BVD15-DO3A(其中GRP靶向配体JG-ABZ4-qwavghlM-NH2和Y1靶向配体INP-K [EPSILON-J-(α-DO3A-EPSILON-DGA) -K] yrlry-nH2偶联),识别出合成,纯化和特​​征在于GRP和Y1受体。具有探针的竞争性位移细胞结合测定测定研究证明了T-47D细胞(18 +/- 0.7nm)中的GRP受体和MCF7细胞中的Y1受体(80 +/- 11nm)中的GRP受体的强亲和力(在括号中给出的IC 50值) 。作为异质双靶探针T-BBN / BVD15-DO3A的进一步评价,本研究的目的是在37℃下确定其小鼠和人血清稳定性。双靶探针的体外代谢降解通过使用GD-153标记的T-BBN / BVD15-DO3A和高性能液相色谱/放射性同位素探测器分析方法研究小鼠和人血清。将小鼠血清中双靶探针的降解的半衰期(T(1/2))计算为7小时,并且在人血清中孵育6小时后观察到20%的降解。可以将双靶探针的体外代谢降解缓慢与相应的单体探针,BVD15-DO3A和AMBA:15的降解T1 / 2进行比较,并且类似于BVD15-DO3A和3.1和38.8小时的40分钟小鼠和人血清的AMBA分别。基于完整探针及其降解剂的色谱保留次数,提出了用于小鼠血清中T-BBN / BVD15-DO3A的体外代谢降解的可能途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号